Table 1.
Patient characteristics of the gastric adenocarcinoma including the four molecular subtypes (according to TCGA), separated into the overall collective, male and female cohort
| Overall collective (n = 458) |
Male cohort (n = 310) |
Female cohort (n = 148) |
||||
|---|---|---|---|---|---|---|
| Preoperative treatment | ||||||
| None | 268 | 58.5% | 176 | 56.8% | 92 | 62.2% |
| Neoadjuvant | 190 | 41.5% | 134 | 43.2% | 56 | 37.8% |
| Age | ||||||
| < 50 | 58 | 13.4% | 33 | 11.1% | 25 | 18.1% |
| > 50 | 376 | 86.6% | 263 | 88.9% | 113 | 81.9% |
| UICC stage | ||||||
| (y)1 | 92 | 22.8% | 63 | 22.9% | 29 | 22.5% |
| (y)2 | 114 | 28.2% | 74 | 26.9% | 40 | 31.0% |
| (y)3 | 137 | 33.9% | 97 | 35.3% | 40 | 31.0% |
| (y)4 | 61 | 15.1% | 41 | 14.9% | 20 | 15.5% |
| Molecular subtype | ||||||
| CIN | 308 | 73.5% | 208 | 74.3% | 100 | 71.9% |
| MSI | 37 | 8.8% | 23 | 8.2% | 14 | 10.1% |
| GS | 55 | 13.1% | 32 | 11.4% | 23 | 16.5% |
| EBV | 19 | 4.5% | 17 | 6.1% | 2 | 1.4% |
| Localisation | ||||||
| Proximal | 186 | 41.6% | 142 | 47.3% | 44 | 29.9% |
| Corpus | 125 | 28.0% | 68 | 22.7% | 57 | 38.8% |
| Distal | 99 | 22.1% | 61 | 20.3% | 38 | 25.9% |
| Other | 37 | 8.3% | 29 | 9.7% | 8 | 5.4% |
TCGA The Cancer Genome Atlas, UICC Union internationale contre le cancer, CIN chromosomal instability, MSI microsatellite instability, GS genomically stable, EBV Epstein–Barr virus-positive